179 related articles for article (PubMed ID: 37139315)
1. The efficacy of homestyle rehabilitation on negative symptoms in chronic schizophrenia: A randomized controlled trial.
Chai J; Liu F; Liu L; Hu N; Huang W; Wang H; Cui Y; Liu H; Li X; Li Y
Front Psychiatry; 2023; 14():1138794. PubMed ID: 37139315
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
3. Assessing negative symptoms in schizophrenia: Validity of the clinical assessment interview for negative symptoms in Singapore.
Rekhi G; Ang MS; Yuen CKY; Ng WY; Lee J
Schizophr Res; 2019 Apr; 206():177-182. PubMed ID: 30558979
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Brief Negative Symptom Scale and its association with functioning.
Ang MS; Rekhi G; Lee J
Schizophr Res; 2019 Jun; 208():97-104. PubMed ID: 30987926
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia.
Majadas S; Olivares J; Galan J; Diez T
Compr Psychiatry; 2012 Feb; 53(2):145-51. PubMed ID: 21621754
[TBL] [Abstract][Full Text] [Related]
6. Improving Pleasure and Motivation in Schizophrenia: A Randomized Controlled Clinical Trial.
Favrod J; Nguyen A; Chaix J; Pellet J; Frobert L; Fankhauser C; Ismailaj A; Brana A; Tamic G; Suter C; Rexhaj S; Golay P; Bonsack C
Psychother Psychosom; 2019; 88(2):84-95. PubMed ID: 30783071
[TBL] [Abstract][Full Text] [Related]
7. [Distinguishing depressive from nondepressive patients in schizophrenia in terms of symptomatology].
Aydemir O; Esen Danaci A; Pirildar S
Turk Psikiyatri Derg; 2002; 13(3):173-8. PubMed ID: 12794651
[TBL] [Abstract][Full Text] [Related]
8. Positive Emotions Program for Schizophrenia (PEPS): a pilot intervention to reduce anhedonia and apathy.
Favrod J; Nguyen A; Fankhauser C; Ismailaj A; Hasler JD; Ringuet A; Rexhaj S; Bonsack C
BMC Psychiatry; 2015 Sep; 15():231. PubMed ID: 26419356
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.
Alvarez E; Ciudad A; Olivares JM; Bousoño M; Gómez JC
J Clin Psychopharmacol; 2006 Jun; 26(3):238-49. PubMed ID: 16702888
[TBL] [Abstract][Full Text] [Related]
11. Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia.
Weng J; Zhang Y; Li H; Shen Y; Yu W
Gen Psychiatr; 2019; 32(1):e100026. PubMed ID: 31179423
[TBL] [Abstract][Full Text] [Related]
12. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
[TBL] [Abstract][Full Text] [Related]
13. Overcoming Disembodiment: The Effect of Movement Therapy on Negative Symptoms in Schizophrenia-A Multicenter Randomized Controlled Trial.
Martin LA; Koch SC; Hirjak D; Fuchs T
Front Psychol; 2016; 7():483. PubMed ID: 27064347
[TBL] [Abstract][Full Text] [Related]
14. The psychometric properties of the Self-Evaluation of Negative Symptoms Scale (SNS) in treatment-resistant schizophrenia (TRS).
Goldring A; Borne S; Hefner A; Thanju A; Khan A; Lindenmayer JP
Schizophr Res; 2020 Oct; 224():159-166. PubMed ID: 33071071
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study.
Kumar S; Chaudhury S
Ind Psychiatry J; 2014 Jan; 23(1):27-35. PubMed ID: 25535442
[TBL] [Abstract][Full Text] [Related]
16. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.
Kinon BJ; Lipkovich I; Edwards SB; Adams DH; Ascher-Svanum H; Siris SG
J Clin Psychopharmacol; 2006 Apr; 26(2):157-62. PubMed ID: 16633144
[TBL] [Abstract][Full Text] [Related]
17. Occupational therapy for inpatients with chronic schizophrenia: a pilot randomized controlled trial.
Foruzandeh N; Parvin N
Jpn J Nurs Sci; 2013 Jun; 10(1):136-41. PubMed ID: 23735098
[TBL] [Abstract][Full Text] [Related]
18. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial.
Iancu I; Tschernihovsky E; Bodner E; Piconne AS; Lowengrub K
Psychiatry Res; 2010 Aug; 179(1):19-23. PubMed ID: 20472299
[TBL] [Abstract][Full Text] [Related]
19. Social recovery therapy for young people with emerging severe mental illness: the Prodigy RCT.
Fowler D; Berry C; Hodgekins J; Banerjee R; Barton G; Byrne R; Clarke T; Fraser R; Grant K; Greenwood K; Notley C; Parker S; Shepstone L; Wilson J; French P
Health Technol Assess; 2021 Nov; 25(70):1-98. PubMed ID: 34842524
[TBL] [Abstract][Full Text] [Related]
20. Improvements in negative symptoms and functional outcome after a new generation cognitive remediation program: a randomized controlled trial.
Sánchez P; Peña J; Bengoetxea E; Ojeda N; Elizagárate E; Ezcurra J; Gutiérrez M
Schizophr Bull; 2014 May; 40(3):707-15. PubMed ID: 23686130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
